Celsion Corp (CLSN): Alberto R Jr Martinez , director of Celsion Corp purchased 5,000 shares on Jun 17, 2016. The Insider buying transaction was reported by the company on Jun 17, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.35 per share for a total value of $6,750.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 16, 2016, Michael H Tardugno (CEO) purchased 7,500 shares at $1.35 per share price.On Feb 16, 2016, Alberto R Jr Martinez (director) purchased 5,000 shares at $1.16 per share price.Also, On Dec 4, 2015, Inc. Fka Egen, Inc. Egwu, (10% owner) sold 5,556 shares at $2.08 per share price.
Celsion Corporation (CLSN) witnessed a volatile trading activity on Wednesday Jun 15, 2016 and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $1.36 and reached the intraday high at $1.36. The bulls started the profit booking and pushed the shares to intraday low of $1.33. The trading session was marked by a volume range of 35,419 shares exchanging hands. The 52-week high of the shares is $2.72 and the 52-week low is $1.04. The market cap of the company stands at $32 M and there are 2,34,36,772 shares in public circulation.
Celsion Corporation (Celsion) is an oncology drug development company. The Company is focused on developing a portfolio of cancer treatments including directed chemotherapies immunotherapies and ribonucleic acid (RNA)- or deoxyribonucleic acid (DNA)-based therapies. Its lead program is ThermoDox a heat-activated liposomal encapsulation of doxorubicin which is in Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1 a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies including TheraPlas and TheraSilence.